Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Mast Makes Board Appointment

This article was originally published in Scrip

Executive Summary

San Diego-based Mast Therapeutics, a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure and stroke has named Peter Greenleaf to its board of directors. Greenleaf currently serves as CEO and a member of the board of Sucampo Pharmaceuticals Inc., which is focused on the development and commercialisation of medicines to meet major unmet medical needs worldwide. He currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Greenleaf is also a member of the board of the Biotechnology Industry Organization (BIO).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register